Floatz logo

Sitravatinib

Urothelial Carcinoma Bladder

Mirati Therapeutics Inc.Small moleculePhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
81/ 100

Competitive context

38 Active assets in the Urothelial Carcinoma Bladder cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Atezolizumab
KaliVir Immunotherapeutics
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Nivolumab
Nagoya University
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Sitravatinib is also rated in:

nonpapillary renal cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →